Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 6/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1746113 | 1.00 | AKR1B10 (0.61) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL2340300 | 0.98 | AKR1B10 (0.60) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL2340303 | 0.98 | AKR1B10 (0.60) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL1744660 | 0.98 | AKR1B10 (0.60) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL1744661 | 0.98 | AKR1B10 (0.60) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL1744179 | 0.98 | AKR1B10 (0.60) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL1744177 | 0.98 | AKR1B10 (0.60) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| SCHEMBL7997849 | 0.98 | AKR1B10 (0.63) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| SCHEMBL7997845 | 0.98 | AKR1B10 (0.63) | AKR1B10AKR1B1LMNAALDH1A1MEN1 | |
| SCHEMBL8007280 | 0.97 | AKR1B10 (0.61) | AKR1B10AKR1B1LMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616087-B2 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | SEIKAGAKU CORPORATION (JP) | 2017-04-11 | — | — | US | disclosed |
| US-9301972-B2 | Hyaluronic acid derivatives | SEIKAGAKU CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150283169-A1 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS | SEIKAGAKU CORPORATION (JP) | 2015-10-08 | — | — | US | disclosed |
| EP-2910248-A1 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | SEIKAGAKU CORPORATION (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20150094280-A1 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS | SEIKAGAKU CORPORATION (JP) | 2015-04-02 | — | — | US | disclosed |
| US-8889652-B2 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | SEIKAGAKU CORPORATION (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2386306-A1 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | SEIKAGAKU CORPORATION (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110053885-A1 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS | SEIKAGAKU CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2094280-A1 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS | SEIKAGAKU CORPORATION (JP) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008069348-A9 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS | SEIKAGAKU KOGYO CO LTD (JP) | 2009-08-20 | — | — | WO | disclosed |
| WO-2008069348-A1 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS | SEIKAGAKU CORPORATION (JP) | 2008-06-12 | — | — | WO | disclosed |